Salud financiera de hoja de balance de TC Biopharm (Holdings)

Salud financiera controles de criterios 5/6

TC Biopharm (Holdings) tiene un patrimonio de los accionistas total de £1.1M y una deuda total de £0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son £7.3M y £6.2M respectivamente.

Información clave

Ratio deuda-patrimonio

UK£0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	UK£980.96k
Patrimonio	UK£1.08m
Total pasivo	UK£6.18m
Activos totales	UK£7.26m

Actualizaciones recientes sobre salud financiera

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (£4.2M) de T0U0 no cubren sus pasivos a corto plazo (£4.8M).

Pasivo a largo plazo: Los activos a corto plazo de T0U0 (£4.2M) superan a sus pasivos a largo plazo (£1.4M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: T0U0 está libre de deudas.

Reducción de la deuda: T0U0 no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: T0U0 tiene suficiente cash runway para 1 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que T0U0 disponga de suficiente cash runway para 1 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de TC Biopharm (Holdings)

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

TC BioPharm Remains Compliant with All Nasdaq Listing Requirements and Continues Trading on the Nasdaq Stock Exchange, Responds to False Social Media Claim

TC Biopharm (Holdings) Provides Non-Compliance Update

TC Biopharm (Holdings) Regains Compliance with the Nasdaq Stock Market Listing Rule 5550(b)

TC Biopharm Receives Notice of Non-compliance with NASDAQ's Listing Rule 5550(b)(1)

Recent updates

TC BioPharm Remains Compliant with All Nasdaq Listing Requirements and Continues Trading on the Nasdaq Stock Exchange, Responds to False Social Media Claim

TC Biopharm (Holdings) Plc Announces Dosing of 5 New Patients in ACHIEVE

TC BioPharm (Holdings) PLC Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications

TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering.

TC Biopharm (Holdings) Plc has completed a Follow-on Equity Offering in the amount of $2 million.

TC BioPharm (Holdings) PLC Announces Dosing of 6th Patient in ACHIEVE Study in Patients with Acute Myeloid Leukemia

TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering.

TC Biopharm (Holdings) Provides Non-Compliance Update

TC Biopharm (Holdings) Plc Announces Launch of Compassionate Use Program for TCB008

TC Biopharm (Holdings) Plc, Annual General Meeting, Mar 14, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc has filed a Follow-on Equity Offering in the amount of $3.5 million.

TC BioPharm (Holdings) PLC Appoints Lauren Bor as Head of Commercial Development Division

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia

TC Biopharm (Holdings) Plc Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia

TC Biopharm (Holdings) Regains Compliance with the Nasdaq Stock Market Listing Rule 5550(b)

TC Biopharm (Holdings) Plc, Annual General Meeting, Jun 29, 2023

Full year 2022 earnings released: UK£2.02 loss per share (vs UK£6.49 loss in FY 2021)

High number of new and inexperienced directors

TC Biopharm Appoints Arlene Morris as New Chair of the Board

TC Biopharm (Holdings) Plc Announces Successful Dosing of Final Patient in ACHIEVE Safety Cohort

TC BioPharm (Holdings) plc Announces the Appointment of Bree Harlin as Chief Clinical Officer

TC Biopharm Receives Notice of Non-compliance with NASDAQ's Listing Rule 5550(b)(1)

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc announced that it has received $7.35 million in funding

TC Biopharm (Holdings) Plc announced that it expects to receive $7.35 million in funding

Tc BioPharm Begins Dosing Phase 2B Clinical Study Evaluating Its Lead Compound, Omnimmune(R), in Patients with Acute Myeloid Leukemia

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc, Annual General Meeting, Nov 14, 2022

TC Biopharm (Holdings) Plc Announces Additions to Scientific Advisory Board

TC Biopharm (Holdings) Plc, Annual General Meeting, Nov 01, 2022

TC Biopharm (Holdings) PLC Receives MHRA Approval for 18-Month Extrapolated Shelf-Life of Allogeneic Cell Therapy Product, OmnImmune

High number of new and inexperienced directors

TC Biopharm (Holdings) Plc has completed a Follow-on Equity Offering in the amount of $4 million.

TC Biopharm Announces Formation of Scientific Advisory Board

TC Biopharm (Holdings) Plc Receives CryoTC Trademark for Proprietary Cell Freezing Process

High number of new directors

TC Biopharm (Holdings) Plc Announces Positive Phase 1b/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic Gamma Delta T Cells

Insufficient new directors

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera